![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current NOV market cap is 335.13B. The company's latest EPS is DKK 22.4617 and P/E is 3.48.
Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
Total Revenue | 126.95B | 140.8B | 176.95B | 232.26B | 290.4B |
Operating Income | 54.28B | 58.62B | 74.62B | 102.66B | 128.32B |
Net Income | 42.14B | 47.76B | 55.53B | 83.68B | 100.99B |
Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
Total Assets | 144.92B | 194.51B | 241.26B | 314.49B | 465.8B |
Total Liabilities | 81.6B | 123.76B | 157.77B | 207.93B | 322.31B |
Total Equity | 63.33B | 70.75B | 83.49B | 106.56B | 143.49B |
Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
Operating | 51.95B | 55B | 78.89B | 108.91B | 120.97B |
Investing | -22.44B | -31.61B | -24.92B | -43.89B | -128.9B |
Financing | -32.24B | -25.49B | -51.8B | -63.16B | 8.74B |
Market Cap | 335.13B |
Price to Earnings Ratio | 3.48 |
Price to Sales Ratio | 1.21 |
Price to Cash Ratio | 22.45 |
Price to Book Ratio | 2.45 |
Dividend Yield | 99.09% |
Shares Outstanding | 4.5B |
Average Volume (1 week) | 184.85k |
Average Volume (1 Month) | 196.72k |
52 Week Change | -33.43% |
52 Week High | 139.88 |
52 Week Low | 9.6779 |
Spread (Intraday) | 0.08 (0.11%) |
Company Name | Novo Nordisk |
Address |
novo alle bagsvaerd DK-2880 |
Website | https://www.novonordisk.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions